tradingkey.logo
搜尋

ImmuCell Corp

ICCC
添加自選
10.290USD
-0.710-6.45%
收盤 07/02, 13:00美東報價延遲15分鐘
93.09M總市值
虧損本益比TTM

ImmuCell Corp

10.290
-0.710-6.45%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-6.45%

5天

+5.11%

1月

+6.41%

6月

+73.82%

今年開始到現在

+67.32%

1年

+55.44%

關鍵數據
10.930今開
10.930最高
41.07K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.45%換手率
11.000昨收
10.070最低
289.75K成交額
虧損本益比靜
3.20市淨率
0.00%股息率 TTM
-1.22%ROA
10.75052週最高
2.02量比
-2.16M淨利潤
9.05M總股本
-0.0617每股盈餘TTM
0.54Beta
-1.88%ROE
4.52052週最低
7.82%振幅
44.97%毛利率
93.09M總市值
3.17回報/風險
2.98%風險率

TradingKey ImmuCell Corp股票評分

單位: USD 更新時間: 2026-07-01

操作建議

ImmuCell Corp當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名102/157位。機構持股佔比非常高,中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ImmuCell Corp評分

相關信息

行業排名
102 / 157
全市場排名
303 / 4564
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

ImmuCell Corp亮點

亮點風險
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
業績高增長
公司營業收入穩步增長,連續3年增長58.22%
業績增長期
公司處於發展階段,最新年度總收入27.64M美元
估值低估
公司最新PE估值-178.28,處於3年歷史低位
機構加倉
最新機構持股2.16M股,環比增加9.59%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間

ImmuCell Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ImmuCell Corp簡介

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
公司代碼ICCC
公司ImmuCell Corp
CEOte Boekhorst (Olivier)
網址https://immucell.com/

常見問題

ImmuCell Corp(ICCC)的當前股價是多少?

ImmuCell Corp(ICCC)的當前股價是 11.00。

ImmuCell Corp 的股票代碼是什麼?

ImmuCell Corp的股票代碼是ICCC。

ImmuCell Corp股票的52週最高點是多少?

ImmuCell Corp股票的52週最高點是10.75。

ImmuCell Corp股票的52週最低點是多少?

ImmuCell Corp股票的52週最低點是4.52。

ImmuCell Corp的市值是多少?

ImmuCell Corp的市值是99.51M。

ImmuCell Corp(ICCC)股票的每股收益(EPS TTM)是多少

ImmuCell Corp(ICCC)股票的每股收益(EPS TTM)是-0.12。